Clinical Trial Update: Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding [Phase 2]

View source ↗

Summary

Phase 2 trial comparing ferric carboxymaltose to iron dextran for iron deficiency anemia due to heavy uterine bleeding; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heavy Menstrual Bleeding
• Iron Deficiency Anemia

Drugs mentioned

• Ferric carboxymaltose (ferric carboxymaltose)
• Iron Dextran (iron dextran)

Snippet

Sponsor: American Regent, Inc. | Conditions: Iron Deficiency Anemia | Phase 2 | Status: COMPLETED | Results posted: 2017-06-27